Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

54.97 -0.20 (-0.36%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
BMRN ALERT: Robbins Geller Rudman & Dowd LLP Announces that BioMarin Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO, CA / ACCESSWIRE / October 27, 2021 / The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) securities between... 
From Robbins Geller Rudman & Dowd LLP
Via AccessWire
Topics Lawsuit
BIOMARIN ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against BioMarin Pharmaceuticals and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Lawsuits Filed Against SAM, BMRN and RECAF - Jakubowitz Law Pursues Shareholders Claims
NEW YORK, NY / ACCESSWIRE / October 27, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies... 
From Jakubowitz Law
Via AccessWire
Topics Fraud Lawsuit
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc... 
Via Benzinga
Biomarin Pharmaceutical: Q3 Earnings Insights
Biomarin Pharmaceutical (NASDAQ:BMRN) reported its Q3 earnings results on Wednesday, October 27, 2021 at 04:05 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
SHAREHOLDER ALERT: INNV HEPS BMRN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, NY / ACCESSWIRE / October 27, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a... 
From The Law Offices of Vincent Wong
Via AccessWire
Topics Fraud Lawsuit
CLASS ACTION UPDATE for EAR, NNOX and BMRN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / October 27, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies.... 
From Levi & Korsinsky, LLP
Via AccessWire
Topics Lawsuit
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
LAWSUITS FILED AGAINST EAR, BMRN and RECAF -Jakubowitz Law Pursues Shareholders Claims
NEW YORK, NY / ACCESSWIRE / October 26, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies... 
From Jakubowitz Law
Via AccessWire
Topics Fraud Lawsuit
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
CLASS ACTION UPDATE for HYRE, WDH and BMRN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / October 26, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies.... 
From Levi & Korsinsky, LLP
Via AccessWire
Topics Initial Public Offering Lawsuit
BMRN ALERT: BioMarin Pharmaceutical Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of KPLT, BMRN and AMRN
NEW YORK, NY / ACCESSWIRE / October 26, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to... 
From The Klein Law Firm
Via AccessWire
Topics Fraud Intellectual Property
SHAREHOLDER ALERT: HEPS BMRN AMRN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, NY / ACCESSWIRE / October 26, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a... 
From The Law Offices of Vincent Wong
Via AccessWire
Topics Fraud Intellectual Property Lawsuit
Lawsuits Filed Against HYZN, NNOX and BMRN - Jakubowitz Law Pursues Shareholders Claims
NEW YORK, NY / ACCESSWIRE / October 25, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies... 
From Jakubowitz Law
Via AccessWire
Topics Fraud Lawsuit
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages BioMarin Pharmaceutical Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – BMRN
From Rosen Law Firm
Via Business Wire
Barron's Latest Picks And Pans: Amazon, Apple, Chevron, Citigroup, Dell And More
This weekend's Barron's cover story features the latest results of the annual Barron's Big Money Poll. Other featured articles discuss which companies may benefit... 
Via Benzinga
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength... 
Via Benzinga
NASDAQ:BMRN Investor Notice: Investigation over Possible Securities Laws Violations by BioMarin Pharmaceutical Inc.
San Diego, CA -- (SBWIRE) -- 09/22/2021 -- BioMarin Pharmaceutical Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Stifel Upgrades This Pharma Stock On Prospective FDA Approval For Dwarfism Drug
Stifel 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2021
Upgrades According to Benchmark, the prior rating for TopBuild Corp (NYSE: 
Via Benzinga
Price To Earnings Ratio Insights For Biomarin Pharmaceutical
In the current market session, Biomarin Pharmaceutical Inc. (NASDAQ:BMRN) is trading at $80.65, after a 5.06% drop. However, over the past month, the stock spiked by... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Pliant Therapeutics (NASDAQ:PLRX) shares rose 25.62% to $24.27 during Tuesday's pre-market session. The market value of their outstanding shares is at $872.2... 
Via Benzinga
FDA Slaps Clinical Hold on BioMarin's Gene Therapy For Genetic Metabolism Disorder
​​​​​​BioMarin Pharmaceutical Inc (NASDAQ: BMRN) faces another setback in its gene therapy development program after the FDA placed the phenylketonuria (PKU) gene... 
Via Benzinga
Drug For Short-Limbed Dwarfism From Biomarin Wins European Approval
The European Commission (EC) has approved BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) Voxzogo (vosoritide) once-daily injection to treat achondroplasia. The... 
Via Benzinga
Get Ready for a Potential Double in This Biopharmaceutical Stock in the Next 6 to 12 Months
All it will take is an FDA approval and a partial repeat of history. 
Via The Motley Fool
BioMarin Bounces Back With Solid Q2 Earnings, Nudges Up 2021 Guidance
BioMarin Pharmaceutical Inc reported a 17% Y/Y increase in revenue to $501.7 million in Q2, beating the consensus of $448.8 million, attributable to Vimizim, Naglazyme, and Palynziq product revenues,... 
Via Talk Markets
BioMarin Bounces Back With Solid Q2 Earnings, Nudges Up 2021 Guidance
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) reported a 17% Y/Y increase in revenue to $501.7 million in Q2, beating the consensus of $448.8 million, attributable to... 
Via Benzinga
BioMarin Pharmaceutical inc (BMRN) Q2 2021 Earnings Call Transcript
BMRN earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Biomarin Pharmaceutical: Q2 Earnings Insights
Shares of Biomarin Pharmaceutical (NASDAQ:BMRN) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 143.75% over the... 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.